Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$16.81 USD
-2.21 (-11.62%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $17.38 +0.57 (3.39%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Cullinan Therapeutics, Inc. [CGEM]
Reports for Purchase
Showing records 1 - 20 ( 53 total )
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
So Far, So Good; Zipalertinib, CLN-619 Data Updates
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -ASCO 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Multiple Pipeline Data Readouts in 2024 Could Move the Stock Higher
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Having the Upper Hand on Blincyto Has Never Been So Valuable
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ASCO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Moving Into Autoimmune Diseases With CLN-978; Private Placement Announced; Lowering PT to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Pivotal Zipalertinib Trial Expected to be Fully Enrolled by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Of Many Shapes and Sizes; Initiating on Cullinan Oncology at OUTPERFORM
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cullinan Announces Dosing of First Patient in Phase 1 Trial of CLN-617
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Cullinan Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for CGEM 112123
Provider: Stock Traders Daily
Analyst: Research Department